Open AccessA Review of Butyrylcholinesterase as a Therapeutic Target in the Treatment of Alzheimer’s Disease
Author(s) -
Agneta Nordberg,
Clive Ballard,
Roger Bullock,
Taher DarrehShori,
Monique Somogyi
Publication year - 2013
Publication title -
primary care companion to cns disorders/the primary care companion for cns disorders
Language(s) - English
Resource type - Journals
eISSN - 2155-7772
pISSN - 2155-7780
DOI - 10.4088/pcc.12r01412
Subject(s) - butyrylcholinesterase , acetylcholinesterase , rivastigmine , cholinergic , cholinesterase , acetylcholine , medicine , disease , aché , pharmacology , bioinformatics , psychology , donepezil , dementia , biology , enzyme , biochemistry
To examine the role of butyrylcholinesterase (BuChE) in cholinergic signaling and neurologic conditions, such as Alzheimer's disease (AD). The rationale for inhibiting cholinesterases in the management of AD, including clinical evidence supporting use of the dual acetylcholinesterase (AChE) and BuChE inhibitor rivastigmine, is discussed.